These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 16178492

  • 1. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
    Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC, BoNTA-039 Study Group.
    Mayo Clin Proc; 2005 Sep; 80(9):1126-37. PubMed ID: 16178492
    [Abstract] [Full Text] [Related]

  • 2. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
    Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C, BOTOX CDH Study Group.
    Headache; 2005 Apr; 45(4):293-307. PubMed ID: 15836565
    [Abstract] [Full Text] [Related]

  • 3. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group.
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [Abstract] [Full Text] [Related]

  • 4. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD, BOTOX CDH Study Group.
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [Abstract] [Full Text] [Related]

  • 5. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 6. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches.
    Relja M, Poole AC, Schoenen J, Pascual J, Lei X, Thompson C, European BoNTA Headache Study Group.
    Cephalalgia; 2007 Jun; 27(6):492-503. PubMed ID: 17428299
    [Abstract] [Full Text] [Related]

  • 7. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine.
    Saper JR, Mathew NT, Loder EW, DeGryse R, VanDenburgh AM, BoNTA-009 Study Group.
    Pain Med; 2007 Sep; 8(6):478-85. PubMed ID: 17716321
    [Abstract] [Full Text] [Related]

  • 8. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
    Mathew NT, Kailasam J, Meadors L.
    Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356
    [Abstract] [Full Text] [Related]

  • 9. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis.
    Elkind AH, O'Carroll P, Blumenfeld A, DeGryse R, Dimitrova R, BoNTA-024-026-036 Study Group.
    J Pain; 2006 Oct; 7(10):688-96. PubMed ID: 17018329
    [Abstract] [Full Text] [Related]

  • 10. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine.
    Blumenfeld AM, Schim JD, Chippendale TJ.
    Headache; 2008 Feb; 48(2):210-20. PubMed ID: 18047502
    [Abstract] [Full Text] [Related]

  • 11. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study.
    Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, Nappi G.
    J Headache Pain; 2011 Aug; 12(4):427-33. PubMed ID: 21499747
    [Abstract] [Full Text] [Related]

  • 12. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [Abstract] [Full Text] [Related]

  • 13. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study.
    Silberstein SD, Göbel H, Jensen R, Elkind AH, Degryse R, Walcott JM, Turkel C.
    Cephalalgia; 2006 Jul; 26(7):790-800. PubMed ID: 16776693
    [Abstract] [Full Text] [Related]

  • 14. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders.
    Blumenfeld A.
    Headache; 2003 Sep; 43(8):853-60. PubMed ID: 12940806
    [Abstract] [Full Text] [Related]

  • 15. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial.
    Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M, GSK1358820 Spasticity Study Group.
    J Neurol; 2010 Aug; 257(8):1330-7. PubMed ID: 20358216
    [Abstract] [Full Text] [Related]

  • 16. Acupoint injection of onabotulinumtoxin A for migraines.
    Hou M, Xie JF, Kong XP, Zhang Y, Shao YF, Wang C, Ren WT, Cui GF, Xin L, Hou YP.
    Toxins (Basel); 2015 Oct 30; 7(11):4442-54. PubMed ID: 26529014
    [Abstract] [Full Text] [Related]

  • 17. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group.
    Headache; 2010 Jun 30; 50(6):921-36. PubMed ID: 20487038
    [Abstract] [Full Text] [Related]

  • 18. Botulinum toxin type A in post-stroke upper limb spasticity.
    Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M, GSK1358820 Spasticity Study Group.
    Curr Med Res Opin; 2010 Aug 30; 26(8):1983-92. PubMed ID: 20569068
    [Abstract] [Full Text] [Related]

  • 19. Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience.
    Farinelli I, Coloprisco G, De Filippis S, Martelletti P.
    J Headache Pain; 2006 Dec 30; 7(6):407-12. PubMed ID: 17149565
    [Abstract] [Full Text] [Related]

  • 20. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study.
    Ondo WG, Vuong KD, Derman HS.
    Cephalalgia; 2004 Jan 30; 24(1):60-5. PubMed ID: 14687015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.